Cord blood transplant for Epstein-Barr virus diseases
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 80 years old.
- You must have a diagnosed EBV-related condition (chronic active EBV infection, EBV-related hemophagocytic syndrome, or EBV-related lymphoma).
- For lymphoma: you must have already tried standard treatment that didn't work or stopped working.
- You must be well enough to get out of bed (ECOG 0-2 or Lansky 60+ for children).
- You cannot have another cancer, uncontrolled infection, severe heart disease, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This early-phase trial tests lab-made “memory” immune T cells that target Epstein-Barr virus (EBV). It may help people whose EBV infection has caused lymphomas or serious complications after a transplant.
Hear when a new Epstein-Barr Virus-associated Lymphoproliferative Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.